{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:53:47Z","timestamp":1790805227049,"version":"4.1.0"},"reference-count":41,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T00:00:00Z","timestamp":1743465600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ascpt.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Clin Pharma and Therapeutics"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:p>A common issue in clinical drug development involves drug\u2013drug interactions (DDI) that may lead to altered drug exposure and subsequent altered safety and efficacy of an investigational drug or concomitant medications (conmeds) in the target patient population. The drug development pipeline therefore involves DDI risk assessment of the investigational drug based on in\u00a0vitro studies, in silico modeling, and clinical trials. Real\u2010world data (RWD), particularly claims databases with reliable information on pharmacy dispensing, provide an opportunity to understand conmeds usage in the target indication in a real\u2010world setting as one approach to assess potential DDI risk. We describe two cases of characterizing DDI\u2010related conmeds usage with a large closed US\u2010based claims database, IQVIA PharMetrics\u00ae Plus, and identified potential DDI risk for multiple sclerosis and hormone receptor\u2010positive breast cancer. For example, prevalent and chronic use of statins (atorvastatin and simvastatin), which are CYP3A4 substrates, were identified among both disease cases. Further examples, limitations, and future directions are also discussed. These insights can therefore help augment decision\u2010making during clinical drug research and development.<\/jats:p>","DOI":"10.1002\/cpt.3652","type":"journal-article","created":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T00:59:54Z","timestamp":1743728394000},"page":"146-155","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Use of Real\u2010World Claims Data to Assess the Prevalence of Concomitant Medications to Inform Drug\u2013Drug Interaction Risk in Target Patient Populations"],"prefix":"10.1002","volume":"118","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4745-0714","authenticated-orcid":false,"given":"Alice S.","family":"Tang","sequence":"first","affiliation":[{"name":"Clinical Pharmacology Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-408X","authenticated-orcid":false,"given":"Logan","family":"Brooks","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Denise M.","family":"Boudreau","sequence":"additional","affiliation":[{"name":"Product Development Data Science and Real World Data Science Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9011-5431","authenticated-orcid":false,"given":"Pascal","family":"Chanu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Genentech\/Roche, Inc.  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0017-2971","authenticated-orcid":false,"given":"Amita","family":"Joshi","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0501-1804","authenticated-orcid":false,"given":"Bianca","family":"Vora","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6266-461X","authenticated-orcid":false,"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[{"name":"Clinical Pharmacology Genentech, Inc.  South San Francisco California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,4]]},"reference":[{"key":"e_1_2_10_1_1","doi-asserted-by":"publisher","DOI":"10.1177\/0091270007312153"},{"key":"e_1_2_10_2_1","unstructured":"The US Food and Drug Administration.Clinical drug interaction studies\u2014cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry<https:\/\/www.fda.gov\/media\/134581\/download> (2020)."},{"key":"e_1_2_10_3_1","unstructured":"The US Food and Drug Administration.In vitro drug interaction studies\u2014cytochrome P450 enzyme\u2010 and transporter\u2010mediated drug interactions guidance for industry<https:\/\/www.fda.gov\/media\/134582> (2020)."},{"key":"e_1_2_10_4_1","unstructured":"The US Food and Drug Administration.Framework for FDA'S real\u2010world evidence program<https:\/\/www.fda.gov\/media\/120060\/download> (2018)."},{"key":"e_1_2_10_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2480"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2988"},{"key":"e_1_2_10_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics14030592"},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1177\/1078155218798150"},{"key":"e_1_2_10_9_1","unstructured":"The US Food and Drug Administration.For healthcare professionals | FDA's examples of drugs that interact with CYP enzymes and transporter systems<https:\/\/www.fda.gov\/drugs\/drug\u2010interactions\u2010labeling\/healthcare\u2010professionals\u2010fdas\u2010examples\u2010drugs\u2010interact\u2010cyp\u2010enzymes\u2010and\u2010transporter\u2010systems> (2023)."},{"key":"e_1_2_10_10_1","unstructured":"Fact Sheet.IQVIA PharMetrics\u00ae Plus<https:\/\/www.iqvia.com\/locations\/united\u2010states\/library\/fact\u2010sheets\/iqvia\u2010pharmetrics\u2010plus> (2022)."},{"key":"e_1_2_10_11_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000007043"},{"key":"e_1_2_10_12_1","unstructured":"Feyman Y.Generic drug utilization and spending among Medicare part D enrollees in 2022. Assistant Secretary for Planning and Evaluation (ASPE) U.S. Department of Health and Human Services <https:\/\/aspe.hhs.gov\/reports\/generic\u2010drug\u2010use\u2010among\u2010part\u2010d\u2010enrollees\u20102022> (2024)."},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103621"},{"key":"e_1_2_10_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2016.21"},{"key":"e_1_2_10_15_1","article-title":"Infectious risk in multiple sclerosis patients treated with disease\u2010modifying therapies: a three\u2010year observational cohort study","volume":"8","author":"Zingaropoli M.A.","year":"2022","journal-title":"Mult. Scler. J. Exp. Transl. Clin."},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13311-021-01008-7"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102184"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10072-020-04727-5"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1197195"},{"key":"e_1_2_10_20_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrneurol.2017.33"},{"key":"e_1_2_10_21_1","doi-asserted-by":"publisher","DOI":"10.2344\/anpr-64-02-10"},{"key":"e_1_2_10_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2011.03.001"},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-16366-6_11"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2020.2388"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41523-024-00638-2"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2016.04.003"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10549-013-2521-2"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jgo.2022.03.007"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.2146\/ajhp060609"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S12955"},{"key":"e_1_2_10_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-54402-9"},{"key":"e_1_2_10_32_1","doi-asserted-by":"publisher","DOI":"10.1177\/1352458514564487"},{"key":"e_1_2_10_33_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000005302"},{"key":"e_1_2_10_34_1","doi-asserted-by":"publisher","DOI":"10.1345\/aph.1L532"},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.24287"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1474-4422(20)30354-9"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-002-0765-6"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.72.2.179"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-020-00938-z"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.2147\/BCTT.S105618"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jcph.6118"}],"container-title":["Clinical Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cpt.3652","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,9]],"date-time":"2025-08-09T07:17:12Z","timestamp":1754723832000},"score":1,"resource":{"primary":{"URL":"https:\/\/ascpt.onlinelibrary.wiley.com\/doi\/10.1002\/cpt.3652"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4]]},"references-count":41,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["10.1002\/cpt.3652"],"URL":"https:\/\/doi.org\/10.1002\/cpt.3652","archive":["Portico"],"relation":{},"ISSN":["0009-9236","1532-6535"],"issn-type":[{"value":"0009-9236","type":"print"},{"value":"1532-6535","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4]]},"assertion":[{"value":"2024-10-28","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-03-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}